![Nathalie Chauret](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nathalie Chauret
Corporate Officer/Principal at BELLUS HEALTH
Nathalie Chauret active positions
Companies | Position | Start | End |
---|---|---|---|
BELLUS HEALTH | Corporate Officer/Principal | 2016-12-31 | - |
Gladius Pharmaceuticals, Inc.
![]() Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Director/Board Member | - | - |
Gladius Pharmaceuticals Corp.
![]() Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Director/Board Member | - | - |
Career history of Nathalie Chauret
Training of Nathalie Chauret
University of Montréal | Graduate Degree |
Statistics
International
Canada | 4 |
United States | 2 |
Operational
Director/Board Member | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Gladius Pharmaceuticals, Inc.
![]() Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Health Technology |
Gladius Pharmaceuticals Corp.
![]() Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Health Technology |
BELLUS Health, Inc.
![]() BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
- Stock Market
- Insiders
- Nathalie Chauret
- Experience